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The effect of purified glycosphingolipids from Leishmania (Leishmania) amazonensis on human lymphopro-
liferation, on expression of human lymphocyte and monocyte markers (CD3, CD4, CD8, CD14, CD19, and
CD45), and on lymphocyte protein kinase C activity was analyzed.
Parasites belonging to the genus Leishmania present two
forms in their life cycle: promastigotes, which multiply in the
midgut of the sandfly vector, and amastigotes, the obligate
intracellular forms which live within macrophage phagolyso-
somes in the vertebrate host. Leishmania (Leishmania) ama-
zonensis is responsible for most cases of human cutaneous
leishmaniasis in the Amazon region of Brazil.
A family of glycosphingolipids (GSLs) was identified in
amastigotes of L. (L.) amazonensis (1, 18, 19). In an earlier
report we demonstrated that GSLs purified from L. (L.) ama-
zonensis amastigotes inhibited the proliferation of murine T
and B cells (2), suggesting that parasite glycosphingolipids may
play a relevant role in leishmaniasis. Data from our studies
were in agreement with those of several reports showing that
GSLs isolated from brain or tumor cells inhibit proliferation of
lymphoid cells (10–12, 16) and that gangliosides inhibit the
expression of the immunoregulatory antigen CD4 (15). Glyco-
sphingolipids can also modify signal transduction through re-
ceptors associated with protein kinase C (PKC) (4–6, 9). These
data prompted us to investigate the effect of these glycocon-
jugates on human lymphoproliferation and on the expression
of lymphocyte and monocyte markers, as well as their possible
role in human lymphocyte PKC activity.
L. (L.) amazonensis (MHOM/BR/1973/M2269) amastigotes
were isolated from foot lesions of infected hamsters, as de-
scribed by Barbie´ri et al. (1). Glycolipids were extracted with a
mixture of isopropanol-hexane-water (55:20:25), and the GSLs
were purified as described previously (18). Acetylated GSLs
were fractionated from other lipids and phospholipids by Flo-
risil chromatography, where lipids and cholesterol are eluted
with 1,2-dichloroethane, glycosphingolipids are eluted with a
mixture of 1,2-dichloroethane–acetone (1:1), and phospholip-
ids are eluted with a mixture of 1,2-dichloroethane–methanol-
water (4:8:2) (17). The GSL fraction was deacetylated with
0.5% sodium methoxide in methanol, neutralized with Dowex
50 (H form), and subjected to DEAE-Sephadex ion ex-
change chromatography in chloroform-methanol-water (30:
60:8) to separate neutral from acidic GSLs. The neutral
GSL fraction purity was analyzed by high-performance thin-
layer chromatography using staining with orcinol-H2SO4 and
Dittmer-Lester reagent, which detect carbohydrates and
phosphodiester linkages, respectively. No contamination with
phospholipids or peptides was detected, as described previ-
ously (2, 18, 19). The effect of amastigote GSLs on T-cell
responses induced by mitogen was analyzed in lymphocytes
purified from human peripheral blood by Ficoll-Hypaque den-
sity gradient centrifugation. The human procedures were ap-
proved by the Ethical Committee for Human Care from Escola
Paulista de Medicina, Universidade Federal de Sa˜o Paulo. The
cells were cultured into 96-well plates (105 cells/well) in RPMI
1640 medium with 10% fetal calf serum and stimulated with 5
g of phytohemagglutinin (PHA) in the presence of different
amounts of purified GSLs. After 72 h at 37°C in 5% CO2, the
cells were pulsed with 0.5 Ci of [3H]thymidine/well for 6 h,
and the [3H]thymidine uptake was determined after filtration
on glass fiber filters. A dose-dependent inhibition of the lym-
phocyte proliferation was observed (Fig. 1). GSLs at concen-
trations of 10, 25, and 50 g/ml induced 45, 55, and 76%
inhibition of [3H]thymidine uptake, respectively. GSLs did not
cause any toxic effect on lymphocytes as measured by trypan
blue exclusion (viability, 95%).
The effect of amastigote GSLs on the expression of lympho-
cyte and monocyte markers was analyzed by fluorescence-ac-
tivated cell sorter (FACS) with a human blood mononuclear
suspension by using monoclonal antibodies conjugated to phy-
coerythrin or fluorescein isothiocyanate directed to Th cells
and to other lymphocyte and monocyte markers (Beckton
Dickinson). The mononuclear cells were washed with phos-
phate saline buffer, fixed in formalin, and gated on the basis of
forward-angle and right-angle scatter, and the fluorescence
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intensity was analyzed by FACS (Beckton Dickinson). As
shown in Fig. 2, amastigote GSLs did not alter the expression
of surface markers (CD3, CD4, CD8, CD14, CD19, and
CD45). Variable concentrations of GSLs (1, 10, and 50 g/ml)
did not change the expression of these markers over a period
of 48 h (data not shown). On the other hand, a mixture of
gangliosides (1 g/ml) quickly induced a selective loss of CD4
(about 90%), confirming previous observations that ganglio-
sides modulate CD4 expression on human T cells (15). These
results indicate that inhibition of lymphoproliferation by Leish-
mania GSLs is not correlated to modifications in the expres-
sion of immunoregulatory surface determinants. In order to
investigate if amastigote GSLs could modulate PKC activity
from human lymphocytes, this enzyme was partially purified
from human peripheral blood (8). About 5  107 cells were
homogenized with a solution containing 20 mM Tris-HCl (pH
7.5), 0.5 mM EDTA, 0.5 mM EGTA, 0.5% Triton X-100, and
25-g/ml aprotinin and leupeptin, incubated on ice for 30 min,
and centrifuged at 12,000  g for 1 min. The supernatant was
applied to a DEAE-cellulose column, and the PKC was eluted
FIG. 1. Inhibition of the PHA-induced human lymphoproliferative
response by GSLs from L. (L.) amazonensis amastigotes. Mononuclear
cells were incubated with PHA for 72 h in the presence of different neutral
GSL concentrations. Five different experiments were carried out, and re-
sults represent the average for triplicate cultures  standard deviations.
FIG. 2. Effect of different concentrations of L. (L.) amazonensis GSLs and gangliosides on lymphocyte and monocyte surface marker
expression. Human mononuclear cells were treated for 48 h with RPMI medium (A), brain bovine gangliosides at a concentration of 1 g/ml (B),
or neutral GSLs at a concentration of 1 g/ml (C), 10 g/ml (D), or 50 g/ml (E) and then analyzed by FACS. Numbers inside parentheses
represent the percentage of cells positively stained for the specified cell surface marker. The lymphocyte population is indicated in green at top
rows. For all analysis performed, the relationship between the mean of fluorescence intensities and size surface counting was very similar, and more
than 95% of the cell populations analyzed were lymphocytes. Results are representative of five experiments.
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with a solution containing 20 mM Tris-HCl (pH 7.5), 0.5 mM
EDTA, 0.5 mM EGTA, 10 mM 2-mercaptoethanol, and 0.2 M
NaCl. The PKC activity was determined in the presence of 50
M acetylated myelin basic protein [Ac-MBP(4-14)], 20 M
ATP, 1 mM CaCl2, 20 mM MgCl2, 4 mM Tris-HCl (pH 7.5),
20- to 25-Ci/ml [-32P]ATP (3,000 Ci/mmol; Amersham), and
a lipid mixture containing 10 M phorbol 1,2-myristate 13-
acetate and 0.28 mg of phosphatidyl serine/ml according to
recommendations of the PKC assay kit (Gibco-BRL) (21).
GSLs were preincubated with the partial purified PKC for 20
min at room temperature before the PKC assay. After incuba-
tion at 30°C for 10 min, aliquots of 25 l (each) were spotted
onto a phosphocellulose disk, which was immersed in 1%
H3PO4 for 5 min and washed with distilled water, and radio-
activity was measured in a -scintillator counter. As shown in
Fig. 3, a dose-dependent inhibition of PKC activity by GSLs
was observed. Concentrations of 12.5, 25, and 50 g/ml were
able to inhibit the phosphorylation of the Ac-MBP(4-14) sub-
strate in 48, 54, and 71%, respectively. The PKC inhibitor used,
peptide PKC(19-36), is based on the pseudosubstrate region
common to the -, -, and -isozymes of PKC and acts as a
potent and specific inhibitor for the Ac-MBP(4-14) substrate
(7). This inhibitor at a concentration of 25 M reduced the
PKC activity 77%.
The PKC activity could not be recovered when higher con-
centrations of phorbol 1,2-myristate 13-acetate and phosphati-
dyl serine were added, indicating that GSLs do not compete
with these activators. Thus, amastigote GSLs apparently down
modulate the PKC activity. Overall analyses of the results pre-
sented here allow us to hypothesize that the remarkable inhi-
bition of lymphoproliferation induced by GSLs purified from
Leishmania would be related to the PKC activity inhibition.
Inhibition of the oxidative burst in Leishmania-infected mac-
rophages was shown to be due to the effect of lipophosphogly-
can (LPG) on PKC activity (3, 13, 14, 20). This inhibition may
represent a critical step for successful establishment of Leish-
mania promastigotes within the host’s macrophages. The re-
sults described here differ from those reported earlier by Mc-
Neely et al. (14), who studied the inhibition of PKC activity
using intact LPG or fragments of LPG of Leishmania (L.)
donovani and intact glycophosphatylinositols (GIPLs) of Leish-
mania (L.) major. LPG and GIPLs, although classified as gly-
colipids, do not present any structural analogy with neutral
GSLs: (i) LPG and GIPLs present lipid moiety composed by
1-O-alkylglycerol and alkylacylglycerol, respectively, whereas
GSLs present ceramide (composed by sphingosine and fatty
acid) as their lipid moiety; (ii) LPGs and GIPLs are phosphor-
ylated glycolipids, whereas GSLs are neutral glycosphingolip-
ids; and (iii) the carbohydrate sequences of LPGs, GIPLs, and
GSLs are distinct. Furthermore, neutral GSLs used in this
study were completely free of LPG or GIPL contamination as
assessed by 1H-nuclear magnetic resonance and immuno-
chemical methods (18). Our results and those of McNeely et al.
(14) may complement each other, demonstrating that different
glycolipids may have a key role in macrophage infection. Thus,
amastigote GSLs could act as immunomodulator molecules
during the progress of cutaneous leishmaniasis, whereas the
early stages of macrophage infection could possibly be modu-
lated by promastigote LPGs.
Currently, we are performing studies aiming to evaluate
whether other T-cell signaling pathways are also altered by
Leishmania GSLs.
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